Complement regulators and inhibitory proteins.
Nat Rev Immunol. 2009; 9: 729-740
The amplification loop of the complement pathways.
Adv Immunol. 2009; 104: 115-149
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
J Clin Invest. 2003; 111: 1181-1190
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.
Blood. 2006; 108: 1267-1279
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.
Blood. 2008; 112: 4948-4952
Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma.
J Thromb Haemost. 2005; 3: 976-982
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
N Engl J Med. 2009; 361: 345-357
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.
J Am Soc Nephrol. 2013; 24: 475-486
The complement alternative pathway and preeclampsia.
Curr Hypertens Rep. 2018; 20: 40
Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.
Br J Haematol. 2010; 148: 37-47
Pregnancy-related thrombotic microangiopathies: clues from complement biology.
Transfus Apher Sci. 2016; 54: 199-202
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.
Br J Haematol. 2012; 158: 323-335
HUS and atypical HUS.
Blood. 2017; 129: 2847-2857
Complement regulatory genes and hemolytic uremic syndromes.
Annu Rev Med. 2008; 59: 293-309
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference.
Kidney Int. 2017; 91: 539-551
Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome.
NEJM. 2019; 368: 2169-2181
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.
J Am Soc Nephrol. 2010; 21: 859-867
Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature.
Obstet Med. 2011; 4: 83-85
Article hemolytic uremic syndrome in pregnancy and postpartum.
Clin J Am Soc Nephrol. 2017; 12: 1237-1247
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Kidney Int. 2015; 87: 1061-1073
The extended use of eculizumab in pregnancy and complement activation–associated diseases affecting maternal, fetal and neonatal kidneys-the future is now?.
J Clin Med. 2019; 8: 407
Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55).
Eur J Immunol. 1992; 22: 1579-1585
A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
Kidney Int. 2018; 93: 450-459
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Nat Rev Nephrol. 2012; 8: 643-657
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Clin J Am Soc Nephrol. 2010; 5: 1844-1859
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
Transfus Apher Sci. 2018; 57: 247-249
Eculizumab for the treatment of preeclampsia/HELLP syndrome.
Placenta. 2013; 34: 201-203
Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia/HELLP syndrome.
BMJ Case Rep. 2019; 12: e228709
Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.
Clin Kidney J. 2013; 6: 243-244
Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
Nephrol Dial Transpl. 2016; 31: 2122-2130
Recurrent case of pregnancy-induced atypical haemolytic uremic syndrome (P-aHUS).
BMJ Case Rep. 2019; 12: e226571
Use of eculizumab during pregnancy in kidney transplant recipients with atypical HUS.
Kidney Int Rep. 2019; 4: 1658
Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.
J Matern Fetal Neonatal Med. 2019; 32: 2853-2859
Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: is it safe?.
Kidney Int Rep. 2019; 4: 733-739
Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review.
Obstet Gynecol. 2020; 135: 46-58
Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report.
BMC Nephrol. 2019; 20: 3-7
Eculizumab in pregnancy: a narrative overview.
J Nephrol. 2019; 32: 17-25
Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
Pediatr Nephrol. 2019; 34: 2601-2604
Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.
Blood. 2014; 124: 211-219
Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Transfusion. 2004; 44: 1149-1158
Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.
Blood. 2001; 98: 2730-2735
STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
Nat Rev Nephrol. 2012; 8: 622-633
Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von willebrand factor links complement and hemostasis-thrombosis.
PLoS One. 2013; 8: e59372
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Blood. 2019; 134: 1095-1105
Current issues in chronic graft-versus-host disease.
Blood. 2014; 124: 374-384
Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2013; 11: 1925-1927
Complement activation in thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2012; 10: 791-798
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.
Thromb Haemost. 2005; 93: 443-452
Complement and cytokine response in acute thrombotic thrombocytopenic purpura.
Br J Haematol. 2014; 164: 858-866
Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy.
Clin J Am Soc Nephrol. 2012; 7: 2100-2106
Preeclampsia: the death of goliath.
Am J Reprod Immunol. 2006; 55: 84-98
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
J Exp Med. 2002; 195: 211-220
Discovery of a spontaneous genetic mouse model of preeclampsia.
Hypertension. 2002; 39: 337-342
Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency.
J Immunol. 2015; 195: 1129-1138
Urinary excretion of C5b-9 in severe preeclampsia tipping the balance of complement activation in pregnancy.
Hypertension. 2013; 62: 1040-1045
Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes.
Obstet Gynecol. 2011; 117: 75-83
Analysis of complement C3 gene reveals susceptibility to severe Preeclampsia.
Front Immunol. 2017; 8: 589
Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss.
J Pathol. 2011; 225: 502-511
Preeclampsia is characterized by placental complement dysregulation.
Hypertension. 2012; 60: 1332-1337
Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.
Am J Obstet Gynecol. 2008; 198: 385.e1-385.e9
The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.
J Matern Neonatal Med. 2012; 25: 2322-2325
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.
Plos Med. 2011; 8: e1001013
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.
Blood. 2008; 112: 4542-4545
Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.
JCI insight. 2018; 3: 5-7
Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome.
Exp Hematol. 2016; 44: 390-398
TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.
J Immunol. 2005; 174: 485-490
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.
J Clin Invest. 2003; 112: 1644-1654
Targeted inhibition of complement activation prevents features of preeclampsia in mice.
Kidney Int. 2011; 79: 331-339
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
Ann Rheum Dis. 2018; 77: 549-555
IMPACT study: IMProve pregnancy in APS with certolizumab therapy.
Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database.
Arthritis Rheumatol. 2018; 70: 1399-1407
Atherosclerosis: current pathogenesis and therapeutic options.
Nat Med. 2011; 17: 1410-1422
Complement: a key system for immune surveillance and homeostasis.
Nat Immunol. 2010; 11: 785-797
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.
Proc Natl Acad Sci USA. 2007; 104: 240-245
Myocardial infarction is a complication of factor H-associated atypical HUS.
Nephrol Dial Transpl. 2010; 25: 2028-2032
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.
Plos Med. 2006; 3: 1957-1967
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
Blood. 2012; 119: 4182-4191
Atypical hemolytic uremic syndrome presenting as acute heart failure—a rare presentation: diagnosis supported by skin biopsy.
J Investig Med High Impact Case Rep. 2019; 7 ()
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
J Med Case Rep. 2014; 8: 307